Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > Who can get to the bottom of things?
View:
Post by JDavenport on Dec 14, 2022 10:35am

Who can get to the bottom of things?

Regulators, no question. We'll talk about it all in a second...
 
But first, yes, Finallytherock is correct. I have always tried to look both ways before crossing the Bioasis street and Ftr is recognizing it, at last. I could never bring myself to be unequivocal about much of anything regarding Bioasis. Finallytherock is maintaining his irrelevance. He's singing Yankee Doodle while the ship is sinking. 
 
Other than meeting her at the AGM in 2018, knowledge of the circumstances of Dr. Deborah Rathjen's firing from Bionomics was the start of my mistrust in her. I defended her in the beginning, saying that being fired after 18 years is kind of positive. But it turned out to be not so positive. (Her performance at the AGM in 2018 was concerning. She didn't know much of anything about Bioasis despite being on the BoD for over a year at that point. And she said some things, and interrupted some things - there were others there who saw it.)
 
And then, as I have described here before, less than 4 months after she became CEO, the Annual Financial Report came out in June 2019. She and I talked about it a few days later. That was when I made a comment about The Large Pharma and GABA-a.
 
GABA-a! Hoo wee! I told her that I was having a look at GABA-a. She asked me why I was looking at GABA-a. I told her it was because it was the subject of the large pharma deal. She asked me how I knew about that. I told her it was in the annual report. She argued with me about that, saying it wasn't in there. It WAS in the filings and she actually argued with me about it. I was both bemused and not so bemused.
 
She signed the Annual filings and she also signed Form 52-109FV1, Certification of Annual Filings, Venture Issuer Basic Certificate, which is there on SEDAR like everything else and states the following:
 
"I, Deborah Rathjen, Chief Executive Officer of Bioasis Technologies Inc., certify the following:
 
1. Review: I have reviewed the annual financial statements and annual MD&A (together, the “annual filings”) of Bioasis Technologies Inc. (the “issuer”) for the financial year ended February 28, 2019."
 
And then document describes what she's certifying.
 
If she reviewed them, she missed the part about GABA-a. She signed the documents without fully knowing what was in them. There's no other way of looking at that.
 
Well, GABA-a was there and stayed in there from the June, 2019 filings until the Q2 filings of October 2020. It's in the records on SEDAR, still there. I wrote on here about GABA-a and Biogen's work with it, although we've never learned the identity of The Large Pharma. Biogen was where former Bioasis director, Dr. Maha Radhakrishnan, M.D. went. She's Biogen's Chief Medical Officer and a Group Senior Vice President. She leaves DrDR in the dust.
 
And then, in June of 2022, Dr. Deborah Rathjen leaked a reference to an Ellipses deal, stating in a presentation that xB3-001 has been "licensed to Ellipses." Was it an accident? I think so. I think she got her presentations mixed up and used a presentation that was possibly created to pitch aspects of this Midatech acquisition to players in the deal. If an Ellipses deal is a fait accompli but waiting to be signed until after the acquisition, then Bioasis likely should have had access to a considerable sum of money, but DrDR may want the Midatech deal more than she wants to take care of Bioasis and its shareholders. 
 
Why was Ellipses in that presentation? It's something that ought to be given to regulators. 
 
Of course, there's my own situation where Dr. Deborah Rathjen blithely stopped paying me with no notice whatsoever, verbal notice or the required written notice, ignoring our contract. Although she has a history of laziness in reading official documents, it is no excuse, not morally, nor legally. If she decided to cut me loose without telling me and by ignoring my contract, and did so because it would upset shareholders, then that may be fraud and I will pursue it as that. The delayed payment of invoices may have been a tactic to keep me in the fold, with the idea that I would consider that I was being something, anything, would keep me around until she felt it was safe to just ignore my contract. Well, that's exactly why I kept on working, thinking that deals were on the way and Bioasis would have the money to catch me up. 
 
Which all leads me to the question, can Dr. Deborah Rathjen be counted upon to negotiate and consummate this Midatech deal in a competent and/or forthright manner? 
 
The combination of Midatech and Bioasis will own only about 23%, maybe 24%, of the resulting company called Biodexa. Ladenburg Thalmann and Lind will together own 17%,. The placees who will be buying the financing controlled by Ladenburg Thalmann will own 56.6%. That means that Lind, Ladenburg Thalmann and the placees together own almost 74% of the company.
 
So the question is, who, exactly, is acquiring Bioasis, because it sure isn't Midatech? It looks to me like Midatech and Bioasis are being acquired by Ladenburg Thalmann and the people they've brought to the table, perhaps with the help of a Bioasis Corporate Presentation stating that xB3-001 has been licensed to Ellipses, the future of xB3 looks great, but don't worry, those Canadian Bioasis shareholders won't understand any of this.
 
And now Bioasis has signed a bridge financing promissory note and owes money to Lind and has pledged the assets of the company (xB3) against loans and may not be able to back out this deal, no matter how shareholders vote, without defaulting on the loans and losing xB3.
 
So, what is the truth in all of this? Who can sort it out?
 
Regulators might help.

But, but, but...

We should discuss whether former Bioasis shareholders can get a win out of 10% ownership of Biodexa. We should have a look at that, especially if Biodexa signs a nice xB3-001 deal with Ellipses, which would mean big things with respect to other deals. It's NASDAQ and things can fly if Stoopid Dayz happen.

Gotta look both ways on this street. You could get struck down by a flivver, or find your dreams on the other side of the street..
 
jd
Comment by amillionorbust on Dec 14, 2022 10:54am
I've been paying very little attention to BTI for the last few years and only stop in here occasionally to see what's happening. I lightened my load of BTI shares  considerably and pursued other stocks with mostly decent success. I'm glad I did. I feel genuinely sorry for the longs. I haven't done a deep dive on how this deal was put together but JD sums it up pretty good and ...more  
Comment by JDavenport on Dec 14, 2022 11:10am
Yes, a short could happen, and then the whole thing sold to a private company for a penny and a bag o' doobies. Those placees with 56.6% and Ladenburg could get that sale done, possibly on schedule and as planned, with DrDR admitted to the venture fund as a partner. Why, a person could lose his shorts in such an eventuality. Also, this share price at 11¢ is a concern. What might the ...more  
Comment by ronrydell on Dec 14, 2022 12:28pm
We need much more clarity on the status of xB3....how does this factor in a future share price.
Comment by JDavenport on Dec 14, 2022 12:36pm
It seems to me that Dr. Deborah Rathjen has been downplaying xB3 so badly that it supports the thought that xB3 will be sold off to a third party after the deal is done. You wouldn't want those Midatech and other shareholders to gain an understanding of what xB3 is really worth. And who cares what the old Bioasis shareholders think. They don't enough to anything about anything. As a bonus ...more  
Comment by JDavenport on Dec 14, 2022 12:38pm
Sorry. Try again... It seems to me that Dr. Deborah Rathjen has been downplaying xB3 so badly that it supports the thought that xB3 will be sold off to a third party after the deal is done. You wouldn't want those Midatech and other shareholders to gain an understanding of what xB3 is really worth. And who cares what the old Bioasis shareholders think. They don't own enough to do ...more  
Comment by fuzzyjr on Dec 14, 2022 1:58pm
This post has been removed in accordance with Community Policy
Comment by fatboy92 on Dec 14, 2022 2:32pm
Yes what a joke of a deal. It took them all these years to come up with this . What a colossal waste of time!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities